Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Status:
Completed
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination
with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced
epithelial ovarian cancer, primarily peritoneal or fallopian tube carcinoma, resistant to
first line platinum and Paclitaxel based chemotherapy.
The study will be carried out in 5-8 Russian and Belarusian sites. A maximum of 32 patients
with metastatic or locally advanced epithelial ovarian cancer, primarily peritoneal or
fallopian tube carcinoma, resistant to first line platinum and Paclitaxel based chemotherapy,
will be enrolled in the study.